A Phase 4 interventional study of Enavogliflozin and Placebo in Obesity and Type 2 Diabetes, sponsored by Korea University Anam Hospital. Recruiting at 1 site in South Korea. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-09-02.
Sponsored by Korea University Anam Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies in Obesity with a site in Korea, Republic of — 35 open to participants now, 46 under way, 27 of them phase 3. Obesity · Korea, Republic of.
Among the 137 studies in Obesity with a site in Korea, Republic of, this one is the 100th largest by planned enrollment of the 117 interventional ones that give a count, is one of 11 that started in 2025, is one of 7 in phase 4, reaches primary completion later than 10 of the 45 other live ones, and was the 102nd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →35 of the 137 studies in Obesity with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, United States, Argentina and 8 more countries
Ages 18+
Eli Lilly and Company · Sites in Korea, Republic of, United States, Belgium and 7 more countries
Ages 6–11
AstraZeneca · Sites in Korea, Republic of, United States, Argentina and 13 more countries
Ages 18+
AstraZeneca · Sites in Korea, Republic of, United States, Argentina and 13 more countries
Ages 18+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–50
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 20 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 49 · Phase 4 7
First in 2005; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 120 across the 117 interventional studies, 704 across the 20 observational. Of the 76 that completed or were terminated, 10 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 137 have an industry lead sponsor. The 10 most frequent:
Korea University Anam Hospital is the lead sponsor of 114 studies on the registry; 33 are open to participants now.
Korea University Anam Hospital has 4 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
10 of the studies in Obesity with a site in Korea, Republic of that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 10 to your calendar (.ics) → With an account.
Among the 137 studies in Obesity with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to analyze the effects of enavogliflozin on heart function and coronary microvascular function in obese patients compared to a placebo, and to evaluate the improvement in cardiopulmonary exercise capacity in these patients.
In recent years, the prevalence of obesity has increased, which acts as a significant risk factor for cardiovascular diseases. Obesity is closely related to reduced microvascular function, increased insulin resistance, and elevated blood pressure, and it is particularly known to be a major cause of heart failure with preserved ejection fraction (HFpEF) and diastolic dysfunction. Coronary microvascular dysfunction (CMD) leads to angina, myocardial infarction, and heart failure, which are associated with increased mortality. CMD has recently gained more importance as one of the key mechanisms of HFpEF. However, CMD often shows poor response to standard treatments, and when not recognized by healthcare providers, it can result in poor outcomes due to a lack of appropriate treatment.
Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors are drugs that inhibit glucose reabsorption by blocking SGLT2 in the proximal tubules of the kidneys, thereby lowering blood sugar. Initially developed as oral hypoglycemic agents, previous randomized controlled studies have shown that they also have significant beneficial effects on heart failure and cardiovascular diseases not only in diabetic patients but also in non-diabetic patients. Recent studies have also demonstrated the effectiveness of SGLT2 inhibitors in patients with HFpEF. SGLT2 inhibitors reduce excessive sodium excretion through urine, which reduces fluid volume, lowers blood pressure, and decreases body weight, but the exact mechanism of their significant effects in cardiovascular diseases is still not fully understood. In particular, research on the effects of SGLT2 inhibitors on microvascular function is still limited. Recently, a randomized controlled study involving 16 diabetic patients reported an increase in myocardial flow reserve after 4 weeks of dapagliflozin administration, while another study involving 90 high-risk cardiovascular diabetic patients showed no significant change in myocardial flow reserve at 13 weeks with empagliflozin. Regarding enavogliflozin, a recent animal study in pigs suggested that it could improve vascular function by intervening in coronary endothelial cell function.
This study hypothesized that enavogliflozin would improve microvascular abnormalities and enhance heart function and cardiopulmonary exercise capacity in obesity-related cardiovascular diseases. Therefore, the objective of this study is to analyze the effects of enavogliflozin on heart function and microvascular function in obese patients compared to a placebo, and to evaluate the improvement in cardiopulmonary exercise capacity in these patients.
Inclusion Criteria: The following criteria must be met for inclusion in the study:
Obesity or Abdominal Obesity:
(BMI) ≥ 25 kg/m², or Waist circumference: Male ≥ 90 cm, Female ≥ 85 cm.
≥ 6.5%, or Fasting blood glucose ≥ 126 mg/dL after 8 hours of fasting, or Currently on antidiabetic medication. Blood test results must be within 3 months prior to enrollment.
Other inclusion criteria:
Age between 20 and 79 years. Patients who have undergone coronary flow velocity reserve testing. For baseline echocardiography, left ventricular diastolic dysfunction will be evaluated structurally (LV dimension, LV mass index, LA size) and hemodynamically (Doppler data, , strain data).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The medication is a soft, orange, bi-convex, triangular film-coated tablet, and it is administered once daily at a dose of 0.3 mg, regardless of meals.
Drug: Enavogliflozin
The placebo is provided by the pharmaceutical company in the form of a tablet that is identical in size, shape, taste, and odor to the active intervention medication.
Drug: Placebo
Patients who are enrolled in the study will undergo adenosine stress tests assessing coronary flow velocity reserve and body composition analysis on the day of registration. Within 2 weeks, cardiopulmonary exercise tests will be performed with exhalation gas analysis. After completing the baseline cardiopulmonary exercise capacity evaluation, patients will be assigned to either the enavogliflozin or placebo group and monitored for adverse effects within one month. Patients without significant adverse effects will continue the assigned treatment, and at 12 weeks, they will undergo re-evaluation of coronary flow velocity reserve, body composition analysis, and cardiopulmonary exercise capacity. Adverse events will be monitored from the date of enrollment through the final evaluation.
Patients who are enrolled in the study will undergo adenosine stress tests assessing coronary flow velocity reserve and body composition analysis on the day of registration. Within 2 weeks, cardiopulmonary exercise tests will be performed with exhalation gas analysis. After completing the baseline cardiopulmonary exercise capacity evaluation, patients will be assigned to either the enavogliflozin or placebo group and monitored for adverse effects within one month. Patients without significant adverse effects will continue the assigned treatment, and at 12 weeks, they will undergo re-evaluation of coronary flow velocity reserve, body composition analysis, and cardiopulmonary exercise capacity. Adverse events will be monitored from the date of enrollment through the final evaluation.
Coronary microvascular function
The changes in coronary flow velocity reserve at 12 weeks compared to baseline in the active drug/placebo groups
Time frame: From enrollment to the end of treatment at 12 weeks
Cardiopulmonary exercise capacity (VO2peak, mL/min/kg)
The changes in cardiopulmonary exercise capacity ((VO2peak, mL/min/kg) at 12 weeks compared to baseline in the active drug/placebo groups
Time frame: From enrollment to the end of treatment at 12 weeks
Body weight (kg)
Changes in body weight (kg) at 12 weeks compared to baseline
Time frame: From enrollment to the end of treatment at 12 weeks
Systolic and diastolic blood pressure (mmHg)
Changes in Systolic and diastolic blood pressure (mmHg) at 12 weeks compared to baseline
Time frame: From enrollment to the end of treatment at 12 weeks
Waist circumference (cm)
Changes in waist circumference (cm) at 12 weeks compared to baseline
Time frame: From enrollment to the end of treatment at 12 weeks
Lipid profile
Changes in total cholesterol (mg/dL), triglycerides (mg/dL), high-density lipoprotein cholesterol (mg/dL), and low-density lipoprotein cholesterol (mg/dL) at 12 weeks compared to baseline
Time frame: From enrollment to the end of treatment at 12 weeks
Hemoglobin A1c (%)
Changes in hemoglobin A1c (%) at 12 weeks compared to baseline
Time frame: From enrollment to the end of treatment at 12 weeks
NT-proBNP (pg/mL)
Changes in NT-proBNP (pg/mL) at 12 weeks compared to baseline
Time frame: From enrollment to the end of treatment at 12 weeks
Self-assessment of sarcopenia (score)
Changes in self-assessment of sarcopenia (score) at 12 weeks compared to baseline
Time frame: From enrollment to the end of treatment at 12 weeks
5-time chair rise test (sec)
Changes in 5-time chair rise test (sec) at 12 weeks compared to baseline
Time frame: From enrollment to the end of treatment at 12 weeks
Body composition analysis - skeletal muscle mass index
Changes in skeletal muscle mass index (kg/m2) at 12 weeks compared to baseline
Time frame: From enrollment to the end of treatment at 12 weeks
Body composition analysis - visceral fat area
Changes in visceral fat area (cm2) at 12 weeks compared to baseline
Time frame: From enrollment to the end of treatment at 12 weeks
Echocardiographic findings - chamber size (mm)
Changes in chamber size (mm) at 12 weeks compared to baseline
Time frame: From enrollment to the end of treatment at 12 weeks
Echocardiographic findings - ejection fraction (%)
Changes in ejection fraction (%) at 12 weeks compared to baseline
Time frame: From enrollment to the end of treatment at 12 weeks
Echocardiographic findings - E/e'
Changes in E/e' at 12 weeks compared to baseline
Time frame: From enrollment to the end of treatment at 12 weeks
Echocardiographic findings - global longitudinal strain (%)
Changes in global longitudinal strain (%) at 12 weeks compared to baseline
Time frame: From enrollment to the end of treatment at 12 weeks
Epicardial Adipose tissue
% change of EAT from baseline to 12weeks
Time frame: % change of EAT from baseline to 12weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Dec 2025, 11 months after the start.
Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 11 months is below that.
Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enavogliflozin
Korea University Anam Hospital →